April 12, 2026 - Daily Briefing: Cross-Border Business Growth

In a significant move for the North American CBD market, Toronto-based GreenLeaf Wellness has announced a $10 million funding round to fuel its expansion into the United States. The investment, led by a consortium of private equity firms, marks one of the largest cross-border deals in the CBD sector this year and signals growing confidence in the industry’s long-term potential.

Details of the Funding and Expansion Plan

GreenLeaf Wellness, established in 2019, has built a strong presence in Canada with a portfolio of CBD-infused wellness products, including tinctures, topicals, and edibles. The company reported a 35% year-over-year revenue increase in 2025, driven by strong demand for non-intoxicating cannabinoid products among Canadian consumers. With the new $10 million in capital, GreenLeaf aims to replicate this success in the U.S., targeting key states where CBD products are widely accepted under state law.

According to a press release from the company, the expansion will focus initially on California, Colorado, and New York—states with established CBD markets and favorable regulatory environments. GreenLeaf plans to establish distribution partnerships with local retailers and invest in marketing campaigns to build brand awareness. Additionally, the company is exploring the possibility of setting up a U.S.-based manufacturing facility to streamline operations and reduce import costs.

Why This Matters for the CBD Industry

The move by GreenLeaf Wellness highlights a broader trend of Canadian CBD companies looking southward for growth opportunities. With Canada’s cannabis market becoming increasingly saturated, many firms see the U.S. as a land of untapped potential, despite ongoing federal uncertainties around CBD regulation. The U.S. market for CBD products is projected to reach $16 billion by 2030, according to market research firm Brightfield Group, making it an attractive destination for international players.

This cross-border expansion also underscores the competitive dynamics at play in the CBD space. As more companies enter the U.S. market, domestic brands may face increased pressure to innovate and differentiate their offerings. For consumers, the influx of international players like GreenLeaf could mean greater product variety and potentially lower prices as competition heats up.

Challenges Ahead for GreenLeaf

Despite the optimism surrounding the deal, GreenLeaf Wellness will need to navigate a complex landscape in the U.S. Federal regulations around CBD remain unclear, with the Food and Drug Administration (FDA) yet to establish a definitive framework for CBD as a dietary supplement or food ingredient. This ambiguity creates risks for companies operating across state lines, as enforcement actions or policy shifts could disrupt business plans.

Additionally, GreenLeaf will need to contend with established U.S. competitors who have already built strong brand loyalty among consumers. Marketing and compliance costs in the U.S. are notoriously high, and the company will need to ensure its products meet varying state-level requirements for labeling, testing, and distribution.

Broader Implications for North American CBD Trade

The GreenLeaf expansion could pave the way for deeper integration of the North American CBD market, potentially influencing trade policies between the U.S. and Canada. Industry observers note that successful cross-border ventures may encourage regulators to harmonize standards for CBD products, reducing barriers to entry for international firms.

For now, GreenLeaf Wellness is positioning itself as a leader in this emerging trend. “We see tremendous opportunity in the U.S. to bring high-quality, sustainably sourced CBD products to consumers who are seeking natural wellness options,” said CEO Amanda Brooks in a statement. “This funding will help us build a foundation for long-term growth.”

As the CBD industry continues to evolve, cross-border investments like this one will play a critical role in shaping market dynamics. CBDChamp will keep readers updated on GreenLeaf’s progress and other international players eyeing the U.S. market in 2026.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.